Abstract:Chk1, a serine/threonine protein kinase that participates in transducing DNA damage signals, is an attractive target due to its involvement in tumor initiation and progression. As a novel Chk1 inhibitor, the triazolone's bioactivity mechanism is not clear. In this study, we carried out an integrated computational study that combines molecular docking, molecular dynamics (MD) simulations, and binding free energy calculations to identify the key factors necessary for the bioactivities. With the aim of discerning the structural features that affect the inhibitory activity of triazolones, MK-8776, a Chk1 inhibitor that reached the clinical stage, was also used as a reference for simulations. A comparative analysis of the triazolone inhibitors at the molecular level offers valuable insight into the structural and energetic properties. A general feature is that all the studied inhibitors bind in the pocket characterized by residues Leu14, Val22, Ala35, Glu84, Tyr85, Cys86, and Leu136 of Chk1. Moreover, introducing hydrophobic groups into triazolone inhibitors is favorable for binding to Chk1, which is corroborated by residue Leu136 with a relatively large difference in the contribution between MK-8776 and five triazolones to the total binding free energies. A hydrogen bond between the polar hydrogen atoms at R-1 and Cys86 can facilitate proper placement of the inhibitor in the binding pocket of Chk1 that favors binding. However, the introduction of hydrophilic groups into the R-2 position diminishes binding affinity. The information provided by this research is of benefit for further rational design of novel promising inhibitors of Chk1.

Structure-Based Quantitative Structure-Activity Relationship Studies of Checkpoint Kinase 1 Inhibitors

3D-QSAR Study of Chk1 Kinase Inhibitors Based on Docking

Molecular Docking and 3D-QSAR Studies on Checkpoint Kinase 1 Inhibitors

Molecular Modeling Study Of Checkpoint Kinase 1 Inhibitors By Multiple Docking Strategies And Prime/Mm-Gbsa Calculation

Structural Requirements of Pyrimidine, Thienopyridine and Ureido Thiophene Carboxamide-Based Inhibitors of the Checkpoint Kinase 1: QSAR, Docking, Molecular Dynamics Analysis.

Pharmacophore Modeling and Virtual Screening Studies of Checkpoint Kinase 1 Inhibitors.

Structure-based and Shape-Complemented Pharmacophore Modeling for the Discovery of Novel Checkpoint Kinase 1 Inhibitors

QSAR Study of Pyrazolo[1,5-A]pyrimidine Derivative Inhibitors of Chk1

3D-QSAR Study for Inhibitors of Cyclin-Dependent Kinase 4

D-QSAR studies on pyrimidine analogues as cyclin-dependent kinase 1 inhibitors

Structural Requirements of Isoquinolones As Novel Selective C-Jun N-terminal Kinase 1 Inhibitors: 2D and 3D QSAR Analyses.

Characterization of the CHK1 allosteric inhibitor binding site.

Combined Pharmacophore Modeling, Docking, And 3d-Qsar Studies Of Plk1 Inhibitors

Design, Synthesis and Biological Evaluation of Thienopyridinones As Chk1 Inhibitors

Validated Quantitative Structure–activity Relationship Analysis of a Series of 2-Aminothiazole Based P56lck Inhibitors

Computational Studies on the Binding Mechanism Between Triazolone Inhibitors and Chk1 by Molecular Docking and Molecular Dynamics

3D-QSAR study of c-Src kinase inhibitors based on docking

Using 3D-QSAR and Molecular Docking Insight into Inhibitors Binding with Complex-Associated Kinases CDK8

Discovery of 4'-(1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-benzonitriles and 4'-(1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-pyridine-2'-carbonitriles as potent checkpoint kinase 1 (Chk1) inhibitors

Structural Determinants Of Cx-4945 Derivatives As Protein Kinase Ck2 Inhibitors: A Computational Study

Design, Synthesis, and Biological Evaluation of 1,4-Bis(2,3-dihydro-5-oxopyrrol-4-yl)-1,3-butadienes as Potential Chk1 Inhibitors